1. Home
  2. RARE vs BC Comparison

RARE vs BC Comparison

Compare RARE & BC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RARE
  • BC
  • Stock Information
  • Founded
  • RARE 2010
  • BC 1845
  • Country
  • RARE United States
  • BC United States
  • Employees
  • RARE N/A
  • BC N/A
  • Industry
  • RARE Biotechnology: Pharmaceutical Preparations
  • BC Homebuilding
  • Sector
  • RARE Health Care
  • BC Consumer Discretionary
  • Exchange
  • RARE Nasdaq
  • BC Nasdaq
  • Market Cap
  • RARE 5.2B
  • BC 5.5B
  • IPO Year
  • RARE 2014
  • BC N/A
  • Fundamental
  • Price
  • RARE $46.51
  • BC $80.76
  • Analyst Decision
  • RARE Strong Buy
  • BC Buy
  • Analyst Count
  • RARE 14
  • BC 14
  • Target Price
  • RARE $86.79
  • BC $89.00
  • AVG Volume (30 Days)
  • RARE 947.6K
  • BC 521.2K
  • Earning Date
  • RARE 11-05-2024
  • BC 10-24-2024
  • Dividend Yield
  • RARE N/A
  • BC 2.16%
  • EPS Growth
  • RARE N/A
  • BC N/A
  • EPS
  • RARE N/A
  • BC 4.01
  • Revenue
  • RARE $522,745,000.00
  • BC $5,444,100,000.00
  • Revenue This Year
  • RARE $27.29
  • BC N/A
  • Revenue Next Year
  • RARE $18.30
  • BC $3.98
  • P/E Ratio
  • RARE N/A
  • BC $19.37
  • Revenue Growth
  • RARE 27.44
  • BC N/A
  • 52 Week Low
  • RARE $37.02
  • BC $69.05
  • 52 Week High
  • RARE $60.37
  • BC $99.68
  • Technical
  • Relative Strength Index (RSI)
  • RARE 36.73
  • BC 40.80
  • Support Level
  • RARE $43.04
  • BC $77.17
  • Resistance Level
  • RARE $46.98
  • BC $83.01
  • Average True Range (ATR)
  • RARE 2.11
  • BC 2.08
  • MACD
  • RARE -0.31
  • BC -0.47
  • Stochastic Oscillator
  • RARE 34.47
  • BC 11.33

About RARE Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.

About BC Brunswick Corporation

Brunswick is a leading manufacturer in the marine recreation industry. The firm has more than 60 brands delivering products across propulsion (outboard, sterndrive, and inboard engines, propulsion-related controls, rigging, and propellers), parts, accessories, and technology, and boats (including well-known brands like Boston Whaler and Sea Ray). It also owns numerous Freedom Boat Club (shared ownership) locations as well as Boateka, which facilitates transactions in the used boat market. Brunswick's focus surrounds building the innovative marine and recreational experiences, technologies, and connections supported by quality and innovation.

Share on Social Networks: